** Shares of biopharma co Halozyme Therapeutics HALO.O rise 2.7% to $59.70
** Merck's MRK.N injectable version of its blockbuster cancer drug Keytruda could face a potential patent challenge from Halozyme, the Wall Street Journal reports
** According to HALO, new version of Keytruda infringes on its patents, the report says
** Injectable version of Keytruda is still in clinical testing and expected to be launched by early 2026
** Stock has risen 42% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.